Zacks Research Has Bearish Estimate for Teleflex Q4 Earnings

Teleflex Incorporated (NYSE:TFX) – Zacks Research reduced their Q4 2024 earnings estimates for shares of Teleflex in a research note issued on Wednesday, January 8th. Zacks Research analyst R. Department now anticipates that the medical technology company will earn $3.83 per share for the quarter, down from their prior forecast of $3.85. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q2 2025 earnings at $3.71 EPS, Q3 2025 earnings at $3.75 EPS, Q4 2025 earnings at $4.18 EPS, FY2025 earnings at $15.16 EPS, Q4 2026 earnings at $4.16 EPS and FY2026 earnings at $16.59 EPS.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, beating analysts’ consensus estimates of $3.38 by $0.11. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. During the same quarter in the prior year, the company posted $3.64 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year.

TFX has been the subject of a number of other research reports. Mizuho dropped their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Truist Financial dropped their target price on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. Finally, Royal Bank of Canada dropped their target price on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Teleflex has a consensus rating of “Moderate Buy” and an average target price of $252.50.

Teleflex Trading Down 1.8 %

NYSE TFX opened at $174.75 on Friday. Teleflex has a 12 month low of $171.69 and a 12 month high of $256.85. The company has a 50-day moving average of $186.33 and a 200-day moving average of $216.34. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The company has a market cap of $8.12 billion, a P/E ratio of 34.74, a P/E/G ratio of 1.84 and a beta of 1.16.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date was Friday, November 15th. Teleflex’s dividend payout ratio is presently 27.04%.

Hedge Funds Weigh In On Teleflex

A number of institutional investors and hedge funds have recently bought and sold shares of TFX. Cromwell Holdings LLC boosted its holdings in Teleflex by 59.0% in the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock worth $33,000 after acquiring an additional 49 shares during the period. Avior Wealth Management LLC boosted its stake in shares of Teleflex by 190.6% during the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock valued at $38,000 after buying an additional 101 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Teleflex during the 3rd quarter valued at approximately $40,000. True Wealth Design LLC boosted its stake in shares of Teleflex by 16,600.0% during the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after buying an additional 166 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Teleflex during the 2nd quarter valued at approximately $42,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.